Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis

References

1. 1.↵
   2. Polman CH,
   3. Reingold SC,
   4. Banwell B, et al

   . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302 doi:10.1002/ana.22366 pmid:21387374

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Dalton CM,
   3. Brex PA,
   4. Miszkiel KA, et al

   . Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002;52:47–53 doi:10.1002/ana.10240 pmid:12112046

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Poser CM,
   3. Paty DW,
   4. Scheinberg L, et al

   . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31 doi:10.1002/ana.410130302 pmid:6847134

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Harris JO,
   3. Frank JA,
   4. Patronas N, et al

   . Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548–55 doi:10.1002/ana.410290515 pmid:1859184

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Simon JH,
   3. Li D,
   4. Traboulsee A, et al

   . Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006;27:455–61 pmid:16484429

   FREE Full Text
6. 6.↵
   2. Wattjes MP,
   3. Barkhof F

   . High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology 2009;51:279–92 doi:10.1007/s00234-009-0512-0 pmid:19277621

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Vrenken H,
   3. Jenkinson M,
   4. Horsfield MA, et al

   ; MAGNIMS Study Group. Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 2013;260:2458–71 doi:10.1007/s00415-012-6762-5 pmid:23263472

   CrossRefPubMed
8. 8.↵
   2. Barkhof F,
   3. Karas GB,
   4. van Walderveen MA

   . T1 hypointensities and axonal loss. Neuroimaging Clin N Am 2000;10:739–52, ix pmid:11359722

   PubMedWeb of Science
9. 9.↵
   2. Rand S,
   3. Maravilla KR,
   4. Schmiedl U

   . Lesion enhancement in radio-frequency spoiled gradient-echo imaging: theory, experimental evaluation, and clinical implications. AJNR Am J Neuroradiol 1994;15:27–35 pmid:8141062

   Abstract/FREE Full Text
10. 10.↵
    2. Gramsch C,
    3. Nensa F,
    4. Kastrup O, et al

    . Diagnostic value of 3D fluid attenuated inversion recovery sequence in multiple sclerosis. Acta Radiol 2015;56:622–27 doi:10.1177/0284185114534413 pmid:24867222

    Abstract/FREE Full Text
11. 11.↵
    2. Cotton F,
    3. Weiner HL,
    4. Jolesz FA, et al

    . MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640–46 doi:10.1212/01.WNL.0000046587.83503.1E pmid:12601106

    CrossRefPubMed
12. 12.↵
    2. Nacif MS,
    3. Arai AE,
    4. Lima JAC, et al

    . Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. J Cardiovasc Magn Reson 2012;14:18 doi:10.1186/1532-429X-14-18 pmid:22376193

    CrossRefPubMed
13. 13.↵
    2. Thomsen HS,
    3. Morcos SK,
    4. Almén T, et al

    ; ESUR Contrast Medium Safety Committee. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013;23:307–18 doi:10.1007/s00330-012-2597-9 pmid:22865271

    CrossRefPubMed
14. 14.↵
    2. Miller DH,
    3. Rudge P,
    4. Johnson G, et al

    . Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988:111(pt 4):927–39 doi:10.1093/brain/111.4.927 pmid:3401689

    Abstract/FREE Full Text
15. 15.↵
    2. Traboulsee A,
    3. Li DK

    . Conventional MR imaging. Neuroimaging Clin N Am 2008;18:651–73, x doi:10.1016/j.nic.2008.07.001 pmid:19068407

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Charil A,
    3. Yousry TA,
    4. Rovaris M, et al

    . MRI and the diagnosis of multiple sclerosis: expanding the concept of “no better explanation.” Lancet Neurol 2006;5:841–52 doi:10.1016/S1474-4422(06)70572-5 pmid:16987731

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Dong-Si T,
    3. Richman S,
    4. Wattjes MP, et al

    . Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014;1:755–64 doi:10.1002/acn3.114 pmid:25493267

    CrossRefPubMed
18. 18.↵
    2. Wattjes MP,
    3. Barkhof F

    . Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 2014;27:260–70 doi:10.1097/WCO.0000000000000099 pmid:24739400

    CrossRefPubMed
19. 19.↵
    2. Yousry TA,
    3. Pelletier D,
    4. Cadavid D, et al

    . Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72:779–87 doi:10.1002/ana.23676 pmid:23280794

    CrossRefPubMed
20. 20.↵
    2. Poonawalla AH,
    3. Hou P,
    4. Nelson FA, et al

    . Cervical spinal cord lesions in multiple sclerosis: T1-weighted inversion-recovery MR imaging with phase-sensitive reconstruction. Radiology 2008;246:258–64 doi:10.1148/radiol.2463061900 pmid:17991786

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Wingerchuk DM,
    3. Banwell B,
    4. Bennett JL, et al

    . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89 doi:10.1212/WNL.0000000000001729 pmid:26092914

    CrossRefPubMed
22. 22.↵
    2. McDonald WI,
    3. Compston A,
    4. Edan G, et al

    . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–27 doi:10.1002/ana.1032 pmid:11456302

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Brex PA,
    3. Ciccarelli O,
    4. O'Riordan JI, et al

    . A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158–64 doi:10.1056/NEJMoa011341 pmid:11796849

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Kang H,
    3. Metz LM,
    4. Traboulsee AL, et al

    ; Minocycline in CIS Study Group. Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes. Mult Scler 2014;20:458–63 doi:10.1177/1352458513501230 pmid:23970502

    Abstract/FREE Full Text
25. 25.↵
    2. Edan G,
    3. Kappos L,
    4. Montalbán X, et al

    ; BENEFIT Study Group. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 2014;85:1183–89 doi:10.1136/jnnp-2013-306222 pmid:24218527

    Abstract/FREE Full Text
26. 26.↵
    2. Beck RW,
    3. Chandler DL,
    4. Cole SR, et al

    . Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002;51:481–90 doi:10.1002/ana.10148 pmid:11921054

    CrossRefPubMedWeb of Science
27. 27.↵
    The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008;65:727–32 doi: doi:10.1001/archneur.65.6.727 pmid:18541792

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Fisniku LK,
    3. Brex PA,
    4. Altmann DR, et al

    . Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131(pt 3):808–17 doi:10.1093/brain/awm329 pmid:18234696

    Abstract/FREE Full Text
29. 29.↵
    2. Okuda DT,
    3. Mowry EM,
    4. Beheshtian A, et al

    . Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800–05 doi:10.1212/01.wnl.0000335764.14513.1a pmid:19073949

    Abstract/FREE Full Text
30. 30.↵
    2. Okuda DT,
    3. Mowry EM,
    4. Cree BA, et al

    . Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011;76:686–92 doi:10.1212/WNL.0b013e31820d8b1d pmid:21270417

    Abstract/FREE Full Text
31. 31.↵
    2. Okuda DT,
    3. Siva A,
    4. Kantarci O, et al

    . Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One 2014;9:e90509 doi:10.1371/journal.pone.0090509 pmid:24598783

    CrossRefPubMed
32. 32.↵
    2. Sombekke MH,
    3. Wattjes MP,
    4. Balk LJ, et al

    . Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 2013;80:69–75 doi:10.1212/WNL.0b013e31827b1a67 pmid:23243070

    Abstract/FREE Full Text
33. 33.↵
    2. Bot JC,
    3. Barkhof F,
    4. Polman CH, et al

    . Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226–33 doi:10.1212/WNL.62.2.226 pmid:14745058

    Abstract/FREE Full Text
34. 34.↵
    2. Miller DH,
    3. Weinshenker BG,
    4. Filippi M, et al

    . Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157–74 doi:10.1177/1352458508096878 pmid:18805839

    Abstract/FREE Full Text
35. 35.↵
    2. Simon JH,
    3. Bermel RA,
    4. Rudick RA

    . Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis. AJNR Am J Neuroradiol. 2014;35:831–32 doi:10.3174/ajnr.A3937 pmid:24699092

    FREE Full Text
36. 36.↵
    2. Rudick RA,
    3. Lee JC,
    4. Simon J, et al

    . Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006;60:236–42 doi:10.1002/ana.20883 pmid:16786526

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Sormani MP,
    3. Bonzano L,
    4. Roccatagliata L, et al

    . Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:268–75 doi:10.1002/ana.21606 pmid:19334061

    CrossRefPubMed
38. 38.↵
    2. Prosperini L,
    3. Gallo V,
    4. Petsas N, et al

    . One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009;16:1202–09 doi:10.1111/j.1468-1331.2009.02708.x pmid:19538207

    CrossRefPubMed
39. 39.↵
    2. Bermel RA,
    3. You X,
    4. Foulds P, et al

    . Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol 2013;73:95–103 doi:10.1002/ana.23758 pmid:23378325

    CrossRefPubMed
40. 40.↵
    2. Sormani MP,
    3. Rio J,
    4. Tintorè M, et al

    . Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013;19:605–12 doi:10.1177/1352458512460605 pmid:23012253

    Abstract/FREE Full Text
41. 41.↵
    2. Rio J,
    3. Castilló J,
    4. Rovira A, et al

    . Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15:848–53 doi:10.1177/1352458509104591 pmid:19542263

    Abstract/FREE Full Text
42. 42.↵
    2. Chard DT,
    3. Brex PA,
    4. Ciccarelli O, et al

    . The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry 2003;74:1551–54 doi:10.1136/jnnp.74.11.1551 pmid:14617714

    Abstract/FREE Full Text
43. 43.↵
    2. Wiendl H,
    3. Toyka KV,
    4. Rieckmann P, et al

    Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255:1449–63 doi:10.1007/s00415-008-0061-1 pmid:19005625

    CrossRefPubMedWeb of Science
44. 44.↵
    2. Freedman MS,
    3. Selchen D,
    4. Arnold DL, et al

    ; Canadian Multiple Sclerosis Working Group. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013;40:307–23 doi:10.1017/S0317167100014244 pmid:23603165

    CrossRefPubMed
45. 45.↵
    2. Hawker K,
    3. O'Connor P,
    4. Freedman MS, et al

    ; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460–71 doi:10.1002/ana.21867 pmid:19847908

    CrossRefPubMedWeb of Science
46. 46.↵
    2. Bloomgren G,
    3. Richman S,
    4. Hotermans C, et al

    . Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870–80 doi:10.1056/NEJMoa1107829 pmid:22591293

    CrossRefPubMedWeb of Science